Effects of glycyrrhizin on immune-mediated cytotoxicity

Journal of Gastroenterology and Hepatology (Australia)

Volumn 12, Issue 3, 1997, Pages 243-248

  Yoshikawa, Masahide ^a,c   Matsui, Yuji ^a   Kawamoto, Hiroshi ^a   Umemoto, Norie ^a   Oku, Kazumi ^a   Koizumi, Masaki ^a   Yamao, Junichi ^a   Kuriyama, Shigeki ^a   Nakano, Hiroshi ^a   Hozumi, Nobumichi ^b   Ishizaka, Shigeaki ^a   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b MOUNT SINAI HOSPITAL   (Canada)

^c Nara Medical University   (Japan)

Author keywords

antigen presentation; apoptosis; glycyrrhizin; T cell mediated cytotoxicity; tumour necrosis factor

Indexed keywords

CD4 ANTIGEN; DACTINOMYCIN; GLYCYRRHIZIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CYTOTOXICITY; HEPATITIS; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 8244257362     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1997.tb00416.x     Document Type: Article

References (42)

1. Suzuki H, Ohta Y, Takino T et al. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis: Double blind trial. Asian Med. J. 1983; 26: 423-38.
2. Fujisawa K, Watanabe Y, Kimura K. Therapeutic approach to chronic active hepatitis with glycyrrhizin. Asian Med. J. 1973; 23: 745-56.
3. Hayashi J, Kashiwagi S, Noguchi J et al. Combination therapy of glycyrrhizin withdrawal and human fibroblast interferon for chronic hepatitis B. Clin. Ther. 1989; 11: 161-9.
4. Finney RSH, Somers GF. The anti-inflammatory activity of glycyrrhetinic acid and derivatives. J. Pharm. Pharmacol. 1958; 10: 613-20.
5. Tangri KK, Seth PK, Parmar SS et al. Biochemical study of anti-inflammatory and anti-arthritic properties of glycyrrhetic acid. Biochem. Pharmacol. 1965; 14: 1277-81.
6. 2. Am. J. Chinese Med. 1986; 14: 131-7.
7. Pompei R, Flore O, Marccialis MA, Pani A, Loddo B. Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature 1979; 281: 689-90.
8. Ito M, Sato A, Hirabayashi K et al. Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus (HIV). Antivir. Res. 1988; 10: 289-98.
9. Kumagai A, Yano S, Otomo M. Study on the corticoidlike action of glycyrrhizin and the mechanism of its action. Endocrinol. Jpn. 1957; 4: 17-27.
10. 4-5α- and 5β-reductase in rat liver. Drug Res. 1979; 29: 647-9.
11. Imawari M, Nomura M, Kaieda T et al. Establishment of a human T-cell clone cytotoxic for both autologous and allogeneic hepatocytes from chronic hepatitis patients with type non-A, non-B virus. Proc. Natl Acad. Sci. USA 1989; 86: 2883-7.
12. Koziel MJ, Dudley D, Wong JT et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J. Immunol. 1992; 149: 3339-44.
13. Mondelli M, Mieli-Vergani G, Alberti A et al. Specificity of T lymphocytes cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: Evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J. Immunol. 1982; 129: 2773-8.
14. Bertoletti A, Ferrari C, Fiaccadori F et al. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc. Natl Acad. Sci. USA 1991; 88: 10 445-9.
15. Sheron N, Lau JYN, Daniel H et al. Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection. J. Hepatol. 1991; 12: 241-5.
16. Yoshioka K, Kakumu S, Arao M, Tsutsumi Y, Inoue M. Tumour necrosis factor α production by peripheral blood mononuclear cells of patients with chronic liver disease. Hepatology 1989; 10: 769-73.
17. Marinos G, Naoumov NV, Rossol S et al. Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology 1995; 108: 1453-63.
18. Alexander JJ, Bey E, Geddes EW et al. Establishment of a continuously growing cell line from a primary carcinoma of the liver. S. Afr. Med. J. 1976; 50: 2124-8.
19. Hennet T, Richter C, Peterhans E. Tumour necrosis factor-α induces Superoxide anion generation in mitochondria of L929 cells. Biochem. J. 1993; 289: 587-92.
20. Watanabe M, Wegmann DR, Ochi A, Hozumi N. Antigen presentation by a B-cell line transfected with cloned immunoglobulin heavy- and light-chain specific for a defined hapten. Proc. Natl Acad. Sci. USA 1986; 83: 5247-51.
21. Watanabe M, Yoshikawa M, Hozumi N. Cytotoxic function of a cloned helper T cell line. Immunol. Lett. 1987; 15: 133-8.
22. Yoshikawa M, Matsumura K, Matsumura Y et al. Effects of ursodeoxycholic acid on antigen presentation. Int. Hepatol. Commun. 1993; 1: 243-9.
23. Yang Y, Mercep M, Ware CF, Ashwell JD. Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: Inhibition of Fas ligand expression by retinoic acid and glucocorticoids. J. Exp. Med. 1995; 181: 1673-82.
24. Warren S. Trypan blue exclusion test of cell viability. In: JE Coligan, AM Kruisbeek, DH Margulies, EM Shevack, W Storober, eds. Current Protocols in Immunology. New York: Greene Publishing Associates and Wiley-Interscience, 1991; A3.3-3.4.
25. 2. J. Clin. Invest. 1992; 89: 794-802.
26. Kaji T, Hiraga S, Yamamoto C et al. Characterization of tumor necrosis factor alpha-induced alternation of glycosaminoglycans in cultured cells: Comparison among vascular smooth-muscle cells, vascular endothelial cells, Chang liver cells and LLC-PK1 cells. Biol. Pharm. Bull. 1993; 16: 834-9.
27. Shiki Y, Shirai K, Saito Y, Yoshida S, Mori Y, Wakashin M. Effect of glycyrrhizin on lysis of hepatocyte membranes induced by anti-liver cell membrane antibody. J. Gastroenterol. Hepatol. 1992; 7: 12-16.
28. Ishida S, Sakiya Y, Ichikawa T, Taira Z, Awazu S. Prediction of glycyrrhizin disposition in rat and man by a physiologically based pharmacokinetic model. Chem. Pharm. Bull. 1990; 38: 212-18.
29. Takahashi M, Nakano S, Takeda I et al. The pharma-cokinetics of the glycyrrhizin and glycyrrhetic acid after intravenous administration of glycyrrhizin for the patients with chronic liver disease caused by type C hepatitis virus. Jpn. J. Gastroenterol. 1995; 92: 1929-36 (in Japanese with English abstract).
30. Ishida S, Sakiya Y, Ichikawa T, Taira Z, Awazu S. Prediction of glycyrrhizin disposition in rat and man with liver failure by a physiologically based pharmacokinetic model. J. Pharmacodyn. 1990; 13: 142-57.
31. + cytotoxic T cells. Proc. Natl Acad. Sci. USA 1994; 91: 4185-9.
32. Hanabuchi S, Koyanagi M, Kawasaki A et al. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc. Natl Acad. Sci. USA 1994; 91: 4930-4.
33. + T cell-mediated cytotoxicity. J. Immunol 1994; 152: 1127-33.
34. Hiramatsu N, Hayashi N, Katayama K et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994; 19: 1354-9.
35. Okazaki M, Hino K, Fujii K et al. Immunohistochemical study of Fas antigen in liver of patients with chronic hepatitis and autoimmune liver disease. Int. Hepatol. Commun. 1995; 3: 285-9.
36. Mita E, Hayashi N, Iio S et al. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem. Biophys. Res. Commun. 1994; 204: 468-74.
37. Larrick JW, Wright SC. Cytotoxic mechanism of tumor necrosis factor-α FASEB J. 1990; 4: 3215-23.
38. Schmid DS, Hornung R, McGrath KM, Paul N, Ruddle NH. Target cell DNA fragmentation is mediated by lymphotoxin and tumor necrosis factor. Lymph. Res. 1987; 6: 195-202.
39. Fehsel K, Kolb-Bachofen V, Kolb H. Analysis of TNFα-induced DNA strand breaks at the single cell level. Am. J. Pathol. 1991; 139: 251-4.
40. Zhang YH, Yoshida T, Isobe K et al. Modulation by glycyrrhizin of the cell-surface expression of H-2 class I antigens on murine tumour cell lines and normal cell populations. Immunology 1990; 70: 405-10.
41. Zhang YH, Isobe K, Nagase F et al. Glycyrrhizin as a promoter of the late signal transduction for interleukin-2 production by splenic lymphocytes. Immunology 1993; 79: 528-34.
42. Abe N, Ebina T, Ishida N. Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice. Microbiol. Immunol. 1982; 26: 535-9.